Lung Cancer Clinical Trial
Official title:
Assessment of Right Ventricular Contractile Reserve Following Lung Resection by Dobutamine Stress Cardiac Magnetic Resonance: a Feasibility Study
NCT number | NCT06465277 |
Other study ID # | awaited |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | July 21, 2023 |
Est. completion date | November 2024 |
Feasibility study investigating CMR dobutamine stress testing before and after lung resection
Status | Recruiting |
Enrollment | 42 |
Est. completion date | November 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - 1) Provision of informed consent 2) Age >16 years 3) Planned elective 1. lobectomy lung resection or 2. oesophagectomy surgery with one lung ventilation or 3. gastrectomy Exclusion Criteria: 1. Pregnancy 2. On-going participation in any investigational research which could undermine the scientific basis of the study 3. Atrial fibrillation at baseline 4. Any contraindication to a. CMR, i. Cardiac pacemaker, artificial heart valve, neurostimulator, cochlear implant ii. Aneurysm clips iii. Metal injuries to the eye iv. Loose metal in a part of the body b. Dobutamine stress testing as per the Society for Cardiovascular Magnetic Resonance64 i. Severe systemic arterial hypertension (=220/120 mmHg) ii. Unstable angina pectoris iii. Severe aortic valve stenosis (peak aortic valve gradient >60mmHg or aortic valve area < 1cm2) iv. Complex cardiac arrhythmias including uncontrolled atrial fibrillation v. Hypertrophic obstructive cardiomyopathy vi. Myocarditis, endocarditis, or pericarditis vii. Uncontrolled heart failure 5. Lung resection specific 1. Wedge, segmental or sub-lobar lung resection 2. Pneumonectomy 3. Isolated right middle lobectomy - |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Belfast Health and Social Care Trust | Belfast | Northern Ireland |
Lead Sponsor | Collaborator |
---|---|
Belfast Health and Social Care Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 1) Feasibility of dobutamine stress CMR to measure RVCreserve following lung resection. | Reliability and variability will be assessed through dual reporting of the CMR images, testing intra-/inter-observer intraclass correlation coefficient (ICC) and coefficient of variation (CV). Study design will allow comparison to our previous resting studies published exercise literature and between pre- and post-operative imaging. | Pre-operative and 2 months post-operative | |
Secondary | 1) Acceptability of the dobutamine stress CMR protocol to patients, by questionnaire | Assessed by patient satisfaction questionnaires rate compared to our previous CMR studies that were performed without dobutamine stress testing. | Pre-operative and 2 months post-operative | |
Secondary | 1) Acceptability of the dobutamine stress CMR protocol to patients, by completion | Assessed by patient recruitment/withdrawal rate compared to our previous CMR studies that were performed without dobutamine stress testing. | Pre-operative and 2 months post-operative | |
Secondary | 2) Incidence of complications related to dobutamine stress CMR | We will assess for the onset of any of the following during the scan
New onset atrial fibrillation Ventricular tachycardia Angina, chest pain, shortness of breath and/or ischaemic ECG changes |
Pre-operative and 2 months post-operative | |
Secondary | 3) Change in RVCreserve change following lung resection | Comparison of the change in RVEF on stress pre- and post-operatively | Pre-operative and 2 months post-operative | |
Secondary | 4) Change in PVreserve change following lung resection | Comparison of change in wave reflection on stress pre- and post-operatively | Pre-operative and 2 months post-operative | |
Secondary | 5) Association between the changes in RVCreserve and markers of cardiac inflammation, BNP | Comparison of change in RVCreserve and the change in BNP | Pre-operative and 2 months post-operative | |
Secondary | 5) Association between the changes in RVCreserve and markers of cardiac inflammation, hsTnT | Comparison of change in RVCreserve and the change in hsTnT. | Pre-operative and 2 months post-operative | |
Secondary | 1) Post-operative change in BNP | Post-operative change in BNP in oesophagectomy compared to lung resection and gastrectomy. | Peri-operative blood samples, pre-op, immediately post-op, post-op days 1 and 2, 4-8 weeks post-op |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|